Clinical trial · Observational
MicroRNA as Markers in Testicular Cancer
MicroRNA-371 as Markers for Disease Activity and as a Tool to Monitor the Effect of Chemotherapy and Early Detection of Recurrence in Patients With Testicular Germ Cell Tumours
NCT04914026CI-TRIAL-00060177recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main objective of this study is establish the performance of miR371 in management of testicular cancer
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-Seminoma Testicular Cancer | — | UNRESOLVED | — |
| Relapse Testicular Cancer | — | UNRESOLVED | — |
| Seminoma | Seminoma | ONTOLOGY_EXACT | 0.98 |
| Stage III Testicular Cancer | Malignant Testicular Neoplasm | CURATED_BROADER | 0.78 |
| Stage II Testicular Cancer | Malignant Testicular Neoplasm | CURATED_BROADER | 0.78 |
| Stage I Testicular Cancer | Malignant Testicular Neoplasm | CURATED_BROADER | 0.78 |
| Stage IV Testicular Cancer | Malignant Testicular Neoplasm | CURATED_BROADER | 0.78 |
| Testicular Germ Cell Cancer | Malignant Testicular Germ Cell Tumor | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (4)
- measure
- miR371 as a biomarker in testicular germ cell cancer at orchiectomy
- timeFrame
- 5 years
- description
- To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at diagnosis
- measure
- miR371 as a biomarker in testicular germ cell cancer at RPLND
- timeFrame
- 5 years
- description
- To estimate the sensitivity and specificity of miR371 in identifying viable tumour cells at RPLND
- measure
- miR371 as a biomarker in testicular germ cell cancer during chemotherapy treatment
- timeFrame
- 5 years
- description
- To estimate the performance of miR371 in monitoring of treatment efficiency (chemotherapy)
- measure
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with suspected testicular cancer, referred to orchiectomy. * Patients diagnosed with testicular germ cell cancer. * Age 18-70 years of age. * Must be able receive information and to consent. Exclusion Criteria: * Other prior or concomitant malignancy (other than testicular cancer). * Other diseases or conditions that hinder the ability to receive information and to participate in follow-up procedures.
References
Publications (0)
Data not yet available
No reference posted for this study.